Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

A high level of exclusions like this makes me wond

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 153778
(Total Views: 681)
Posted On: 06/19/2024 3:33:01 AM
Posted By: ohm20
Re: mfglola #144559
A high level of exclusions like this makes me wonder about the credibility of the study. For instance - "participants who did not have a sufficient T1w image quality, including excessive motion artifact and insufficient gray matter-white matter contrast". The image quality should have been noticeable immediately and could have been redone. That they waited to exclude after the trial ended could mean they were actually excluded based on failure of treatment. This is the possible shenanigans you look out for when looking at trial results.

Quote:
Analyses were conducted on all OVERTURE participants who met none of the exclusion criteria: The exclusion criteria for white matter volumetric analyses were as follows: (a) participants who declined > 4 standard deviations from the mean in multiple efficacy measures (1 sham participant excluded); (b) participants who did not have both baseline and end of study (i.e., Month 6) data for structural MRI (22 participants excluded, of which 21 of them did not complete the trial); (c) participants who did not have a sufficient T1w image quality, including excessive motion artifact and insufficient gray matter-white matter contrast (13 participants excluded). Overall, thirty-eight participants (25 Treatment and 13 Sham) were included in white matter volumetric assessments. Of the thirty-eight participants, two failed T2w image quality due to reconstruction error, and a total of thirty-six participants (24 Treatment and 12 Sham) were included for longitudinal T1w/T2w white matter myelin content assessments. Noninvasive Gamma Sensory Stimulation May Reduce White Matter and Myelin Loss in Alzheimer’s Disease



(13)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us